Clinical Trials on HPV Vaccine Knowledge in Ireland

Total 345 results

Glaxo Wellcome

Completed

A Comparative Trial of Valacyclovir Hydrochloride ( 256U87 ) and Acyclovir for the Suppression of Anogenital Herpes Infections in HIV-Infected Patients

HIV Infections | Herpes Simplex

United States
National Institute of Allergy and Infectious Diseases...
Massachusetts General Hospital; National Heart, Lung, and Blood Institute (NHLBI) and other collaborators

Completed

Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults (REPRIEVE)

Cardiovascular Diseases | HIV Infections

Brazil, Spain, United States, Puerto Rico, Haiti, Zimbabwe, Botswana, South Africa, Thailand, Uganda, India, Peru, Canada
ViiV Healthcare
GlaxoSmithKline

Terminated

Strategy-confirming Study of BMS-955176 to Treat HIV-1 Infected Treatment-experienced Adults

HIV Infections

United States, Taiwan, Peru, Canada, Thailand, Australia, Puerto Rico, Russian Federation, Argentina, Mexico, Colombia, South Africa, Chile
Pharmacia and Upjohn

Completed

A Double-Blind, Randomized, Comparative Study of Delavirdine Mesylate (U-90152S) in Combination With Didanosine (ddI) Versus ddI Alone in HIV-1 Infected Individuals With CD4 Counts of <= 300/mm3

HIV Infections

United States, Puerto Rico
ViiV Healthcare

Completed

Expanded Access Program for Maraviroc At Multiple Centers

HIV Infections

Canada, United States, Spain, Switzerland, Malaysia, France, Italy, Portugal, Puerto Rico, Mexico, Australia, Ireland, Romania, Greece, United Kingdom, Argentina, Austria, Belgium, Chile, Costa Rica, Dominican Republic, Germany, Hong... and more
Abbott

Completed

A Study to Compare Two Anti-HIV Drug Combinations in HIV-Infected Patients Who Have Previously Received Anti-HIV Treatment

HIV Infections

United States, Canada, Switzerland, France, Germany, United Kingdom, Brazil, Austria, Australia, Denmark, Poland, South Africa, Spain, Puerto Rico
Gilead Sciences
Janssen Research & Development, LLC

Completed

Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults

HIV Infections | Acquired Immunodeficiency Syndrome

United States, Puerto Rico
Pharmacia and Upjohn

Completed

A Double-Blind, Randomized, Dose Response Study of Three Doses of Delavirdine Mesylate (U-90152S) in Combination With Zidovudine (ZDV) Versus ZDV Alone in HIV-1 Infected Individuals With CD4 Counts of 200-500mm3

HIV Infections

United States, Puerto Rico
Boehringer Ingelheim

Completed

Tipranavir/Ritonavir vs. Genotypically Defined Protease Inhibitor/Ritonavir in HIV Patients (RESIST-2)

HIV Infections

Argentina, Austria, Belgium, Brazil, Denmark, France, Germany, Greece, Ireland, Italy, Mexico, Netherlands, Portugal, Spain, Sweden, Switzerland, United Kingdom
National Institute of Allergy and Infectious Diseases...

Completed

Comparison of Three Different Initial Treatments Without Protease Inhibitors for HIV Infection

HIV Infections

United States, Puerto Rico
National Institute of Allergy and Infectious Diseases...
Bristol-Myers Squibb; Glaxo Wellcome

Completed

A Comparison of Zidovudine Plus Lamivudine Versus ddI Used Alone or in Combination With Zidovudine in HIV-1 Infected Children

HIV Infections

United States, Puerto Rico
Hoffmann-La Roche

Completed

A Comparison of Three Anti-HIV Drug Combinations Containing Saquinavir Soft Gelatin Capsules Used in HIV-1 Infected Patients

HIV Infections

United States, Puerto Rico, Spain, Germany, Italy, United Kingdom
Gilead Sciences

Completed

Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2 and 3 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Adults

Hepatitis C | Human Immunodeficiency Virus

United States, Puerto Rico
ViiV Healthcare
Janssen, LP

Completed

A Study to Evaluate Efficacy and Safety of Cabotegravir (CAB) Long Acting (LA) Plus (+) Rilpivirine (RPV) LA Versus BIKTARVY® (BIK) in Participants With Human Immunodeficiency Virus (HIV)-1 Who Are Virologically Suppressed (SOLAR)

HIV Infections

United States, Netherlands, Germany, Canada, Australia, Belgium, France, Spain, Ireland, Italy, United Kingdom, Austria, Japan, Switzerland
AbbVie

Active, not recruiting

Study to Evaluate Adverse Events and Change in Disease Activity in Adult and Adolescent Participants With Acute Hepatitis C Virus (HCV) Infection on Treatment With Oral Tablets of Glecaprevir (GLE)/Pibrentasvir (PIB)

Hepatitis C Virus (HCV)

United States, Australia, Austria, Canada, France, Germany, Italy, Spain
Abbott

Completed

A Phase III Study Comparing Two Different Anti-HIV Drug Combinations in HIV-Positive Patients Without Previous Anti-HIV Drug Therapy

HIV Infections

United States, Canada, Puerto Rico, Switzerland, France, Germany, United Kingdom, Australia, Brazil, Austria, Denmark, Poland, South Africa, Spain
The Immune Response Corporation

Completed

A Multicenter, Double-Blind, Phase III, Adjuvant-Controlled Study of the Effect of 10 Units of HIV-1 Immunogen (Remune) Compared to Incomplete Freund's Adjuvant (IFA) Alone Every 12 Weeks on AIDS-Free Survival in Subjects With HIV Infection and CD4 T-Lymphocytes Between 300 and 549 Cells/microL Rega

HIV Infections

United States
Boehringer Ingelheim

Completed

VERxVE Study on Efficacy and Safety of Nevirapine XR in Comparison to Nevirapine IR With Truvada in Naive HIV+ Patients

HIV Infections

United States, Argentina, Australia, Belgium, Botswana, Canada, France, Germany, Ireland, Italy, Mexico, Netherlands, Poland, Portugal, Puerto Rico, Romania, Russian Federation, South Africa, Spain, Switzerland, United Kingdom
Gilead Sciences

Terminated

Efficacy and Safety Study of GS-9450 Treatment for 6 Months in Patients With Chronic Hepatitis C Virus Infection

HCV Infection

United States, United Kingdom, Germany, Canada, Puerto Rico, Poland
Boehringer Ingelheim

Completed

Randomized Evaluation of Strategic Intervention in Multidrug Resistant Patients With Tipranavir (RESIST)

HIV Infections

United States, Australia, Canada, Puerto Rico
Rigshospitalet, Denmark
University College, London

Enrolling by invitation

EuroSIDA - Clinical and Virological Outcome of European Patients Infected With HIV (EuroSIDA)

End Stage Liver Disease | Cardiovascular Diseases | Fractures, Bone | Diabetes Mellitus | Renal Insufficiency | Hepatitis B | Hepatitis C | Kidney Failure, Chronic | Proteinuria | HIV | Coinfection | Acidosis, Lactic | AIDS

Spain, Switzerland, Germany, United Kingdom, Austria, Sweden, Finland, Israel, Denmark, France, Italy, Iceland, Belgium, Slovakia, Norway, Lithuania, Portugal, Poland, Croatia, Czechia, Greece, Hungary, Luxembourg, Argentina, Belarus, Bosnia... and more
National Institute of Allergy and Infectious Diseases...

Completed

A Comparison of Two Ways to Manage Anti-HIV Treatment (The SMART Study)

HIV Infections

United Kingdom, Argentina, Switzerland, France, Brazil, United States, Estonia, Spain, Australia, Peru, Austria, Belgium, Canada, Germany, Ireland, Israel, Italy, Japan, Lithuania, Luxembourg, Martinique, New Zealand, Norway, Poland, Puerto... and more
AbbVie

Completed

A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (TOPAZ-II)

Chronic Hepatitis C Virus (HCV) Infection Genotype 1

United States
Abbott

Completed

Study of Lopinavir/Ritonavir Tablets Versus Soft Gel Capsules and Once Daily Versus Twice Daily Administration, When Coadministered With Nucleoside Reverse Transcriptase Inhibitors in Antiretroviral Naive Human Immunodeficiency Virus Type 1 Infected Subjects

Human Immunodeficiency Virus Infections

United States, Australia, Belgium, Canada, Czech Republic, France, Germany, Greece, Ireland, Italy, Netherlands, Poland, Puerto Rico, Russian Federation, Singapore, Spain, Switzerland, Taiwan, United Kingdom
ViiV Healthcare
GlaxoSmithKline

Completed

Dose Ranging Study of GSK1265744 Plus Nucleoside Reverse Transcriptase Inhibitors for Induction of Human Immunodeficiency Virus-1 (HIV-1) Virologic Suppression Followed by Virologic Suppression Maintenance by GSK1265744 Plus Rilpivirine

HIV Infections | Infection, Human Immunodeficiency Virus

United States, Canada
ViiV Healthcare
GlaxoSmithKline; Janssen Pharmaceuticals

Completed

A Phase IIb Study to Evaluate a Long-Acting Intramuscular Regimen for Maintenance of Virologic Suppression (Following Induction With an Oral Regimen of GSK1265744 and Abacavir/Lamivudine) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected, Antiretroviral Therapy-Naive Adult Subjects

HIV Infections | Infection, Human Immunodeficiency Virus

Germany, Spain, France, United States, Canada
Gilead Sciences

Completed

Safety and Efficacy of E/C/F/TDF Versus RTV-Boosted ATV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment-Naive Women (WAVES)

HIV Infections | Acquired Immunodeficiency Syndrome

United States, Thailand, France, Uganda, United Kingdom, Belgium, Portugal, Mexico, Dominican Republic, Italy, Puerto Rico, Russian Federation
AbbVie

Completed

A Study of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment-Naive Adults With Chronic Hepatitis C Virus (HCV) Genotype 1-6 Infection and Compensated Cirrhosis (EXPEDITION-8)

Hepatitis C Virus (HCV)

United States, Bulgaria, Canada, Czechia, France, Greece, Hungary, Ireland, Israel, Italy, Poland, Portugal, Puerto Rico, Romania, Russian Federation, Spain, Taiwan, United Kingdom, Vietnam
ViiV Healthcare

Active, not recruiting

Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients

HIV Infections

United States, Spain, France, Australia, Germany, Belgium, Canada, Argentina, Brazil, Italy, Romania, Mexico, Taiwan, Netherlands, South Africa, Russian Federation, Greece, Portugal, United Kingdom, Poland, Peru, Chile, Colombia, Ireland and more
ViiV Healthcare
GlaxoSmithKline; Janssen Pharmaceuticals

Active, not recruiting

Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants

HIV Infections

United States, Germany, Netherlands, Spain, France, Canada, United Kingdom, Italy, South Africa, Russian Federation, Japan
Bristol-Myers Squibb

No longer available

Atazanavir for HIV Infected Individuals: An Early Access Program

HIV Infections

United States, Puerto Rico
ViiV Healthcare
GlaxoSmithKline

Terminated

Dose-finding Study of BMS-955176 to Treat HIV-1 Infected Treatment-naive Adults

Infection, Human Immunodeficiency Virus

United States, France, Germany, Canada, Spain, United Kingdom, Mexico, Italy, Argentina, Chile, South Africa, Poland
ViiV Healthcare
GlaxoSmithKline

Completed

Dolutegravir Compared to Darunavir/Ritonavir , Each in Combination With Dual Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in ART-naive Subjects (FLAMINGO)

Infection, Human Immunodeficiency Virus

Spain, France, Germany, United States, Italy, Romania, Russian Federation, Switzerland, Puerto Rico
ViiV Healthcare
GlaxoSmithKline; Shionogi

Completed

A Study to Assess Dolutegravir in HIV-infected Subjects With Treatment Failure on an Integrase Inhibitor Containing Regimen. (VIKING-3)

Infection, Human Immunodeficiency Virus

United States, Spain, France, Canada, Portugal, Italy, Belgium
Boehringer Ingelheim

Approved for marketing

Tipranavir in Patients With Progressive, Systemic HIV-1 Disease Who Have Failed or Are Intolerant to Currently Approved Treatments for HIV Infection

HIV Infections

United States, Australia, Belgium, Denmark, France, Greece, Ireland, Italy, Portugal, South Africa, Switzerland, United Kingdom
Janssen R&D Ireland

Completed

Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Regimen Versus Boosted Protease Inhibitor (bPI) Along With Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) Regimen in Virologically-Suppressed, HIV-1 Infected Participants

Human Immunodeficiency Virus Type 1

United States, France, United Kingdom, Belgium, Spain, Switzerland, Sweden, Canada, Puerto Rico, Poland
OMNI Medical Services, LLC
OMNI Medical Services Inc

Recruiting

Outcomes Mandate National Integration With Cannabis as Medicine (OMNI-Can)

Depression | COVID-19 | Epilepsy | Multiple Sclerosis | Glaucoma | Cancer | Covid19 | Chronic Pain | Parkinson Disease | Inflammatory Bowel Diseases | Hepatitis C | Insomnia | HIV/AIDS | Amyotrophic Lateral Sclerosis | Fibromyalgia | Anxiety | Bipolar Disorder | Seizures | Crohn Disease | Traumatic Brain Injury | Ulcerative Colitis | Sickle... and other conditions

United States
Tibotec Pharmaceuticals, Ireland

Approved for marketing

TMC114-C226: An Early Access Program to Evaluate the Long-term Safety and Tolerability of TMC114 Combined With a Low Dose of Ritonavir (TMC114/r) With Other Antiretrovirals, for HIV-1 Infected Patients Who Have Failed Multiple Antiretroviral Regimens.

HIV Infections

United States, Belgium, Germany, Taiwan, Spain, Switzerland, Mexico, Slovenia, Malaysia, Turkey, Canada, Netherlands, Denmark, Greece, Sweden, Russian Federation, Czech Republic, Puerto Rico, Thailand, Hungary, Luxembourg, Venezuela
ViiV Healthcare
GlaxoSmithKline; Shionogi

Completed

A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)

Infection, Human Immunodeficiency Virus I

United States, Spain, Germany, Australia, Canada, Belgium, Denmark, Netherlands, United Kingdom, France, Italy, Romania
National Cancer Institute (NCI)

Completed

Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas

HIV Infection | Recurrent Grade 3 Follicular Lymphoma | Plasmablastic Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Primary Effusion Lymphoma | AIDS-Related Primary Effusion Lymphoma | Ann Arbor Stage I Diffuse Large B-Cell Lymphoma | Ann Arbor Stage II Diffuse Large B-Cell Lymphoma | Ann Arbor... and other conditions

United States
ViiV Healthcare
GlaxoSmithKline; PPD

Completed

An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 1)

HIV Infections | Infection, Human Immunodeficiency Virus

Taiwan, France, Germany, Belgium, United States, Canada, Netherlands, Spain, Korea, Republic of, Italy, Australia, United Kingdom, Russian Federation, Portugal, Argentina, South Africa, Romania, Mexico
AbbVie

Completed

A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (TOPAZ-I)

Chronic Hepatitis C Virus (HCV) Infection Genotype 1

Algeria, Australia, Belgium, Bulgaria, Canada, Denmark, Finland, France, Germany, Greece, Israel, Italy, Mexico, Netherlands, Norway, Poland, Portugal, Romania, Russian Federation, Saudi Arabia, Spain, Switzerland, Turkey, Austria, Ireland and more
ViiV Healthcare
GlaxoSmithKline; Shionogi

Completed

A Study of GSK1349572 Versus Raltegravir (RAL) With Investigator Selected Background Regimen in Antiretroviral-Experienced, Integrase Inhibitor-Naive Adults (SAILING)

HIV Infections | Infection, Human Immunodeficiency Virus

United States, France, Netherlands, Spain, Taiwan, Australia, Belgium, Russian Federation, Canada, United Kingdom, Mexico, Italy, South Africa, Romania, Argentina, Hungary, Poland, Chile, Greece, Brazil
National Cancer Institute (NCI)
NRG Oncology; Canadian Cancer Trials Group

Active, not recruiting

Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin

Head and Neck Squamous Cell Carcinoma | Oropharyngeal Squamous Cell Carcinoma | Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Stage III Hypopharyngeal Carcinoma AJCC v8 | Stage III Laryngeal Cancer AJCC v8 | Stage III Lip and Oral Cavity Cancer AJCC v8 | Stage... and other conditions

United States, Canada
National Cancer Institute (NCI)

Recruiting

Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers

Recurrent Head and Neck Squamous Cell Carcinoma | Recurrent Hypopharyngeal Squamous Cell Carcinoma | Recurrent Laryngeal Squamous Cell Carcinoma | Metastatic Head and Neck Squamous Cell Carcinoma | Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Stage IV Hypopharyngeal... and other conditions

United States

Clinical Trials on HPV Vaccine Knowledge in Ireland

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Cyprus

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations